Coxibs: The new super aspirins or unsafe pain killers?

Indian Journal of Pharmacology

Volumn 37, Issue 2, 2005, Pages 86-89

  Kulkarni, S K ^a   Jain, N K ^b  

^a PANJAB UNIVERSITY   (India)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse effects; COX 2 inhibitors; NSAIDs; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOROLAC; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; ROFECOXIB; VALDECOXIB;

ARTHRITIS; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; MEDICAL ETHICS; PAIN; REVIEW; SIDE EFFECT; STROKE;

EID: 17444405234     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.15107     Document Type: Review

References (38)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
2. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors and lessons from the clinic. FASEB J 2004;18:790-804.
3. Herschman HR, Talley JJ, DuBois R. Cyclooxygenase-2 (COX-2) as target for therapy and noninvasive imaging. Mol Imaging Biol 2003;5:286-303.
4. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
5. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
6. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 2002;47:349-55.
7. Fowles RE. Potential cardiovascular effects of COX-2 selective nonsteroidal anti-inflammatory drugs. J Pain Palliat Care Pharmacother 2003;17:27-50.
8. Deray G. Renal and cardiovascular effects of non-steroidal anti-inflammatories and selective COX- 2 inhibitors. Presse Med 2004;33:483-9.
9. Dewitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 1988;85:1412-6.
10. Herschman HR. Historical aspects of COX-2: Cloning and characterization of the cDNA, protein and gene. In: Harris RE, editor. COX-2 blockade in cancer prevention and therapy. Clifton: N.J. Humana Press; 2003. p. 13-32.
11. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase -1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002;99:13926-31.
12. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
13. Futaki N, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Iizuka H, et al. NS-398, a novel nonsteroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993;24:105-10.
14. Futaki N, Takahashis S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-938, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthases cyclo-oxygenase (COX-2) activity in vitro. Prostaglandins 1994;47:55-9.
15. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:12013-7.
16. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Doctor S, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl] benze nesulfonamide (SC-58635, celecoxib). J Med Chem 1997;40:1347-65.
17. Prasit P, Riendeau D. Selective COX-2 inhibitors. In: Annual reports in medicinal chemistry: 32. Hagmann WK, editor. San Diego: Academic Press; 1997.
18. Lamarque D. Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period. Bull Cancer 2004;91:117-24.
19. Mukherjee D, Nissen, SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
20. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, et al. Cardiovascular thrombotic events in controlled clinical trials of rofecoxib. Circulation 2001;104:2280-8.
21. White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002;89:425-30.
22. Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac and nabumetone). Am J Cardiol 2002;89:204-9.
23. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective nonsteroidal anti-inflammatory drugs and risks of serious coronary heart disease. Lancet 2002;360:1071-3.
24. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, et al. Relationship between selective COX-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
25. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study. Lancet 2004;363:1751-6.
26. Vioxx [homepage on internet]. Press release.[cited: 2004 Nov 18]. Available from: http://www.vioxx.com
27. Couzin J. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 2004;306:384-5.
28. US Food and drug administration [homepage on internet]. Center for Drug evaluation and research.[cited: 2004 Nov 18]. Available from: http://www.fda.gov/cder
29. Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med 2001;110 Suppl 3A:28-32.
30. Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, et al. Effects of selective COX-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 2001;104:820-5.
31. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: Randomized controlled trial. Lancet 2004;364:675-84.
32. Fitzgerald GA. Coxibs and cardiovascular disease. New Engl J Med 2004;351:1709-11.
33. Topol EJ, Falk GW. A coxib a day won't keep the doctor away. Lancet 2004;364:639-40.
34. Jain NK, Patil CS, Kartasasmita RE, Decker M, Lehmann J, Kulkarni SK. Pharmacological studies on nitro-naproxen (naproxen-2-nitroxyethylester). Drug Develop Res 2004;61:66-78.
35. Kulkarni SK, Jain NK, Singh A. Nitric oxide releasing - NSAIDs: A new dimension in non-steroidal anti-inflammatory drugs. Drugs Future 2001;26:485-9.
36. Burgaud JL, Ongini E, Del Soldato P. Nitric oxide releasing NSAIDs: a novel class of effective and safe therapeutic agents. Ann NY Acad Sci 2002;962:360-71.
37. Alvaro-Garcia JM. Licofelone-clinical update on a novel LOX/COX inhibitor for treatment of osteoarthritis. Rheumatology 2004;43:121-5.
38. Bias P, Buchner A, Klesser B, Laufer S. The gastrointestinal tolerability of the LOX/COX inhibitor, Licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: Results from a randomized controlled trial. Am J Gastroenterol 2004;99:611-8.